Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia

Background: Familial combined hyperlipidaemia (FCH), characterized by elevated very-low-density lipoprotein (VLDL) and/or low-density lipoprotein (LDL), is associated with an increased prevalence of premature cardiovascular disease. Therefore, lipid-lowering is frequently indicated. Methods: We eval...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Netherlands journal of medicine 1996-08, Vol.49 (2), p.59-67
Hauptverfasser:	Bredie, S.J.H., Westerveld, H.T., Knipscheer, H.C., de Bruin, T.W.A., Kastelein, J.J.P., Stalenhoef, A.F.H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Apolipoprotein C-III Apolipoproteins B - blood Apolipoproteins B - drug effects Apolipoproteins C - blood Apolipoproteins C - drug effects Biological and medical sciences Cholesterol - blood Clinical trial Double-Blind Method Enzyme Inhibitors - therapeutic use Female Gemfibrozil - therapeutic use General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemia, Familial Combined - blood Hyperlipidemia, Familial Combined - drug therapy Hypolipidemic Agents - therapeutic use Lipids Lipoprotein(a) - blood Lipoprotein(a) - drug effects Lovastatin - analogs & derivatives Lovastatin - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Simvastatin Therapeutics Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!